Table 1.
The clinical parameters and treatments between the two groups.
| Characteristics | SIB-IMRT group (n = 83) | Non-SIB-IMRT group (n = 68) | P value |
|---|---|---|---|
| Age (range) | 57 (20–83) | 58 (31–81) | – |
| Gender | |||
| Male | 58 (69.9%) | 45 (66.2%) | 0.627 |
| Female | 25 (30.1%) | 23 (33.8%) | |
| Pretreatment CEA | |||
| < 5mol/L | 36 (43.4%) | 34 (50.0%) | 0.697 |
| ≥ 5 mol/L | 41 (49.4%) | 29 (42.6%) | |
| unidentified | 6 (7.2%) | 5 (7.4%) | |
| Distance from anal (range) | 4 (0–8) cm | 5 (0–8) cm | – |
| Long axis of tumor (range) | 4.8 (1.8–15) cm | 5 (2.5–10.5) cm | |
| Clinical T stage | |||
| T2 | 3(3.6%) | 2 (2.9%) | 0.279 |
| T3 | 55 (66.3%) | 37 (54.4%) | |
| T4 | 25 (30.1%) | 29 (42.6%) | |
| T3 subgroup | |||
| T3a | 6 (7.2%) | 1 (1.5%) | 0.346 |
| T3b | 42 (50.6%) | 31 (45.6%) | |
| T3c | 7 (8.3%) | 5 (7.4%) | |
| T3d | 0 | 0 | |
| Clinical N stage | |||
| N1 | 27 (32.5%) | 26 (38.2%) | 0.465 |
| N2 | 56 (67.5%) | 42 (61.8%) | |
| Short axis of LPLN (range) | 8 (7–20) mm | 8 (7–15) mm | – |
| <8 mm | 31(37.3%) | 26(38.2%) | 0.911 |
| ≥8 mm | 52(62.7%) | 42(61.8%) | |
| Long axis of LPLN (range) | 8 (7–30) mm | 10 (7–21) mm | – |
| <10 mm | 36(43.4%) | 28(41.2%) | 0.786 |
| ≥10 mm | 47(56.6%) | 40(58.8%) | |
| MRF Status | |||
| Positive | 47(56.6%) | 34 (50.0%) | 0.417 |
| Negative | 36 (43.4%) | 34 (50.0%) | |
| EMVI Status | |||
| Positive | 39 (47.0%) | 36 (52.9%) | 0.467 |
| Negative | 44 (53.0%) | 32 (47.1%) | |
| Synchronous chemotherapy | |||
| Capecitabine | 48 (57.8%) | 57 (83.8%) | 0.001 |
| Capecitabine+Oxaliplatin | 35 (42.2%) | 11 (16.2%) | |
| Neoadjuvant chemotherapy | |||
| CapOX | 25 (30.1%) | 23 (33.8%) | 0.498 |
| Capecitabine | 26 (31.3%) | 25 (36.8%) | |
| None | 32 (38.6%) | 20 (29.4%) |
LPLN, lateral pelvic lymph node; CEA, carcinoembryonic antigen; MRF, mesorectal fascia; EMVI, extramural vascular invasion.